In a study of diagnostic bone marrow and peripheral blood samples obtained from 945 patients with AML (ages 18–60 years), Gaidzik et al. identified 59 RUNX1 mutations, which predicted chemotherapy resistance, inferior event-free survival, recurrence-free survival, and overall survival [3]. Here, RUNX1 is linked to acute myeloid leukemia.